Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Central Nervous System Tumors
- Surgical Oncology
- Head and Neck Oncology
- Bladder Cancer
- Chemoprevention
- General Oncology
- Adjuvant Therapy
- Stomach Cancer
Abstract
Citation: Clin Oncol. 2017;2(1):1218.DOI: 10.25107/2474-1663.1218
Choline PET/CT Imaging for Management of Prostate Cancer
Kazuhiro Kitajima, Kazuhito Fukushima, Koichiro Yamakado, Shozo Hirota and Shingo Yamamoto
Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medicine, Japan
Department of Radiology, Hyogo College of Medicine, Japan
Department of Urology, Hyogo College of Medicine, Japan
*Correspondance to: Kazuhiro Kitajima
PDF Full Text Mini Review | Open Access
Abstract:
Whole-body Positron Emission Tomography/Computed Tomography (PET/CT) with [11C]- and [18F]-labeled choline derivatives has emerged as a promising molecular imaging modality for evaluation of prostate cancer. 11C-choline and 18F-flurocholine PET/CT examinations have been shown to be effective for restaging of prostate cancer patients with biochemical disease recurrence after undergoing definitive therapy, especially those with a serum prostate-specific antigen level >1.0 ng/mL. On the other hand, they have more limited roles for initial staging of prostate cancer or detection of tiny lymph node metastasis, due to the low spatial resolution inherent with PET. Overall, these modalities are most useful for cases with a high pre-test suspicion of metastatic disease. Here, we review the current clinical roles of 11C-choline and 18F-fluorocholine PET/CT for management of patients with prostate cancer.
Keywords:
prostate cancer; Staging; Restaging; 11C-choline; 18F-fluorocholine; Positron emission tomography/computed tomography (PET/CT)
Cite the Article:
Kitajima K, Fukushima K, Yamakado K, Hirota S, Yamamoto S. Choline PET/CT Imaging for Management of Prostate Cancer. Clin Oncol. 2017; 2: 1218.